Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Ind-Swift Laboratories's average EBITDA Per Share Growth Rate was 102.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -37.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -13.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ind-Swift Laboratories was 121.40% per year. The lowest was -65.60% per year. And the median was 4.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ind-Swift Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:INDSWFTLAB vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -37.60% mean?
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a 3-Year EBITDA Growth Rate of -37.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ind-Swift Laboratories and its competitors. According to the industry distribution chart, Ind-Swift Laboratories ranks #771 out of 808 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is Ind-Swift Laboratories' 3-Year EBITDA Growth Rate too high?
Ind-Swift Laboratories' current 3-Year EBITDA Growth Rate is -37.60%. Based on the distribution chart, Ind-Swift Laboratories ranks #771 out of 808 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ind-Swift Laboratories has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #771 out of 808 companies for 3-Year EBITDA Growth Rate. This places Ind-Swift Laboratories in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ind-Swift Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current 3-Year EBITDA Growth Rate is -37.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹51.25, compared to a current price of ₹327.27 — trading 538.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -37.60%. Ind-Swift Laboratories' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current 3-Year EBITDA Growth Rate is -37.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹327.27 is trading 538.6% above its estimated GF Value™ of ₹51.25.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
3-Year EBITDA Growth Rate: -37.60%
GF Value™: ₹51.25 vs. price of ₹327.27 (538.6% above fair value)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
49GF Score
Get the complete analysis for NSE:INDSWFTLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
